-
The frequency of chemotherapy-induced amenorrhea was found to be greater than 90% in premenopausal breast cancer patients treated with standard adjuvant chemotherapy.
-
Carboplatin-pemetrexed doublet chemotherapy is effective primary treatment for patients with nonsquamous non-small cell lung cancer, but the applicability of standard dosing to older or more frail patients was uncertain.
-
Arthralgias and associated symptoms are common among postmenopausal breast cancer patients treated with aromatase inhibitors.
-
Selumetinib, a selective MEK1/2 inhibitor, achieved objective responses in 15% of patients with recurrent low-grade serous ovarian cancer. The data are relevant as this uncommon tumor type is associated with general chemoresistance, frequent aberration in the MAPK pathway, and prolonged overall survival compared with its more common high-grade variant. Phase 3 trials are planned.
-
-
Carboplatin-pemetrexed doublet chemotherapy is effective primary treatment for patients with nonsquamous non-small cell lung cancer, but the applicability of standard dosing to older or more frail patients was uncertain.
-
In a large population of Caucasian women participating in the Womens Health Initiative Observational Study, those who used aspirin had a significantly lower risk of melanoma and increased duration of use was associated with incrementally greater protection.
-
Ten years of adjuvant tamoxifen is significantly better than the standard 5 years of treatment. Continuing adjuvant tamoxifen for 10 years substantially reduces rates of both recurrence and breast cancer-specific mortality in women with estrogen receptor-positive breast cancer.
-
The experience from Harbin, China, in the treatment of de novo acute promyelocytic leukemia (APL) in patients 60 years and older demonstrates the efficacy and safety of single agent arsenic trioxide. This agent with or without all trans retinoic acid may ultimately prove optimal for induction and maintenance APL treatment in older adults.
-
In examining the National Comprehensive Cancer Network Colorectal Database, reasons for not completing the recommended postsurgical chemotherapy were examined. Although only 17% of patients for whom adjuvant therapy was recommended failed to receive treatment, the decision to not proceed was based on a number of factors, most notably the existence of comorbidities. In comparison to this cohort of patients treated at academic centers, the percent of patients not treated with adjuvant chemotherapy is likely to be greater in the community setting.
